

Merck's commitment to American innovation



For 135 years, Merck has brought important medicines and vaccines to the patients who need them.

Between 2018 and 2024, we invested more than **\$80 billion in U.S.-based research and development (R&D)**.

And we're making substantial investments in the next generation of biopharmaceutical innovation.

We are advancing the broadest and most diverse pipeline in our company's recent history:

**Approximately
80 Phase 3 studies
across multiple
therapeutic areas**



In 2025, Merck committed to investing more than **\$70 billion** to expand domestic manufacturing and R&D — not including investments associated with future business development — to support long-term growth and strengthen U.S. leadership in biopharmaceutical innovation.

Investments in R&D infrastructure across our U.S. sites — including the construction and expansion of new facilities, advanced robotics, AI and high-throughput technologies — are designed to strengthen every stage of the R&D process, enabling our scientists to generate insights faster, make more informed decisions and advance medicines and vaccines for patients.


ADVANCE

Strengthening the foundation for future innovation

The latest addition to our West Point, Pennsylvania site exemplifies our investment in cutting-edge capabilities to support our expanding and increasingly complex pipeline.



The facility brings together advanced robotics, automation, real-time data management, modular construction and innovative flexible laboratory design to optimize deployment, transform clinical assay testing and support future scientific needs.



Together with our facility at the nearby Spring House Innovation Park, ADVANCE represents an approximately **\$550 million** investment in R&D to the West Point, PA region, demonstrating our commitment to building the infrastructure required to support future pipeline growth.

Merck has made significant capital investments to the West Point site totaling more than \$15 billion over the past 35 years. The capital investments at West Point have continuously sustained an on-site workforce of approximately 800 contracting, engineering, and construction jobs during this time. Many of these capital projects have been designed in Pennsylvania and represent more than \$1 billion in services provided by locally based architects.

Merck continues to make strategic capital and non-capital investments across its R&D network to accelerate development, strengthen decision-making and transform scientific innovation.

\$850 million+

FLEx Center — Rahway, NJ (2022)

Our state-of-the-art formulation, laboratory and experimentation (FLEx) center, enabling teams to rapidly adapt to evolving pipeline needs while strengthening the connection between product development and manufacturing.

\$400 million+

BDC — Rahway, NJ (2025)

Our integrated Biologics Development Center (BDC), designed to accelerate the development and scale-up of biologic medicines.

\$1 billion+

MACS Facility— Rahway, NJ (2027)

Our upcoming Modality Agnostic Chemistry Scale-Up (MACS) facility, designed to expand Merck's ability to advance next-generation therapeutic modalities by providing flexible process development and manufacturing capabilities that help move candidates from development into clinical studies.